Treatment characteristics
Characteristic∗ . | Overall N = 50 . | Arm A: AZA + ENA n = 27 . | Arm B: ENA n = 23 . |
---|---|---|---|
Time to best response, mo | 2 (1-8) | 1 (1-4) | 5 (3-8) |
Cycles received | 6 (1-32) | 4 (1-32) | 7 (1-29) |
Study disposition | |||
On study | 7 (14) | 4 (15) | 3 (13) |
HSCT | 8 (16) | 7 (26) | 1 (4.3) |
Treatment failure/intolerance | 9 (18) | 3 (11) | 6 (26) |
Progressive MDS | 6 (12) | 1 (3.7) | 5 (22) |
Progression to AML | 6 (12) | 3/27 (11) | 3 (13) |
Death | 9 (18) | 6/27 (22) | 3 (13) |
Patient decision/withdrew consent | 4 (8.0) | 3/27 (11) | 1 (4.3) |
Unknown | 1 (2.0) | — | 1 (4.3) |
HSCT (any time) | 11 (22) | 7/27 (26) | 4 (17) |
Postprotocol therapy | 17 (34) | 6/27 (22) | 11 (48) |
Median number of subsequent therapies | 1 (1-2) | 1 (1-2) | 2 (1-2) |
Venetoclax therapy | 11/17 (65) | 2/6 (33) | 9/11 (82) |
Reason for change in therapy | |||
Progression to AML | 5 (29) | 3 (50) | 2 (18) |
Progressive MDS | 4 (24) | — | 4 (36) |
Treatment failure/intolerance | 8 (47) | 3 (50) | 5 (45) |
Time to next therapy (d) | 10 (0-214) | 9 (0-214) | 10 (0-125) |
Characteristic∗ . | Overall N = 50 . | Arm A: AZA + ENA n = 27 . | Arm B: ENA n = 23 . |
---|---|---|---|
Time to best response, mo | 2 (1-8) | 1 (1-4) | 5 (3-8) |
Cycles received | 6 (1-32) | 4 (1-32) | 7 (1-29) |
Study disposition | |||
On study | 7 (14) | 4 (15) | 3 (13) |
HSCT | 8 (16) | 7 (26) | 1 (4.3) |
Treatment failure/intolerance | 9 (18) | 3 (11) | 6 (26) |
Progressive MDS | 6 (12) | 1 (3.7) | 5 (22) |
Progression to AML | 6 (12) | 3/27 (11) | 3 (13) |
Death | 9 (18) | 6/27 (22) | 3 (13) |
Patient decision/withdrew consent | 4 (8.0) | 3/27 (11) | 1 (4.3) |
Unknown | 1 (2.0) | — | 1 (4.3) |
HSCT (any time) | 11 (22) | 7/27 (26) | 4 (17) |
Postprotocol therapy | 17 (34) | 6/27 (22) | 11 (48) |
Median number of subsequent therapies | 1 (1-2) | 1 (1-2) | 2 (1-2) |
Venetoclax therapy | 11/17 (65) | 2/6 (33) | 9/11 (82) |
Reason for change in therapy | |||
Progression to AML | 5 (29) | 3 (50) | 2 (18) |
Progressive MDS | 4 (24) | — | 4 (36) |
Treatment failure/intolerance | 8 (47) | 3 (50) | 5 (45) |
Time to next therapy (d) | 10 (0-214) | 9 (0-214) | 10 (0-125) |
AZA, azacitidine; ENA, enasidenib.
Values are presented as median (range), n (%), or n/N (%).